Key facts
- It has raised $136.5M; the latest was Later Stage VC ($39.5M) in Mar 2026.
- Notable investors include BDC Capital, OrbiMed, Investissement Quebec, Fonds de solidarite FTQ, Dimension (United States) — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Congruence Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Congruence Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Congruence Therapeutics
Operator of a computationally-driven biotechnology company intended to discover novel drugs. The company uses structural bioinformatics, computational chemistry, and machine learning to design new pharmacological stabilizers at an accelerated pace and scale, providing biotechnology organizations with the ability to correct the pathogenesis of disease with predictive models to identify new pharmaceutical stabilizers for diseases of protein misfolding
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 41
- Website
- congruencetx.com/
- Ownership
- Privately Held (backing)
Congruence Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Congruence Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Congruence Therapeutics in its N-PORT filings yet. We sweep new filings monthly.